U. Bruntsch

1.1k total citations
55 papers, 834 citations indexed

About

U. Bruntsch is a scholar working on Oncology, Surgery and Molecular Biology. According to data from OpenAlex, U. Bruntsch has authored 55 papers receiving a total of 834 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 15 papers in Surgery and 15 papers in Molecular Biology. Recurrent topics in U. Bruntsch's work include Chronic Lymphocytic Leukemia Research (7 papers), Cancer Treatment and Pharmacology (7 papers) and Nausea and vomiting management (6 papers). U. Bruntsch is often cited by papers focused on Chronic Lymphocytic Leukemia Research (7 papers), Cancer Treatment and Pharmacology (7 papers) and Nausea and vomiting management (6 papers). U. Bruntsch collaborates with scholars based in Germany, Netherlands and Switzerland. U. Bruntsch's co-authors include W. M. Gallmeier, M. Clavel, Cornelis J.A. Punt, Marlies Peters, Joseph Boni, J. Renard, J. Wanders, Herbert M. Pinedo, Jaap Verweij and M. van Glabbeke and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

U. Bruntsch

51 papers receiving 786 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
U. Bruntsch Germany 16 319 282 198 173 107 55 834
P Cappelaere France 15 395 1.2× 140 0.5× 267 1.3× 216 1.2× 65 0.6× 66 855
Junichi Kaganoi Japan 20 381 1.2× 380 1.3× 299 1.5× 215 1.2× 87 0.8× 37 1.0k
Carlos García Girón Spain 20 680 2.1× 203 0.7× 184 0.9× 433 2.5× 117 1.1× 96 1.1k
Dolores Gallardo‐Rincón Mexico 18 524 1.6× 494 1.8× 165 0.8× 275 1.6× 96 0.9× 49 1.3k
Xavier Fabregat Spain 14 392 1.2× 233 0.8× 187 0.9× 165 1.0× 41 0.4× 27 740
Thomas Cerny Switzerland 16 508 1.6× 229 0.8× 182 0.9× 443 2.6× 153 1.4× 28 966
K. Buser Switzerland 12 409 1.3× 130 0.5× 323 1.6× 111 0.6× 90 0.8× 17 875
Siu‐Fun Wong United States 14 475 1.5× 249 0.9× 36 0.2× 185 1.1× 51 0.5× 33 886
Suzanne M. Fields United States 12 385 1.2× 167 0.6× 111 0.6× 143 0.8× 49 0.5× 15 610
Ilaria Imarisio Italy 15 317 1.0× 351 1.2× 59 0.3× 489 2.8× 57 0.5× 40 954

Countries citing papers authored by U. Bruntsch

Since Specialization
Citations

This map shows the geographic impact of U. Bruntsch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by U. Bruntsch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites U. Bruntsch more than expected).

Fields of papers citing papers by U. Bruntsch

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by U. Bruntsch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by U. Bruntsch. The network helps show where U. Bruntsch may publish in the future.

Co-authorship network of co-authors of U. Bruntsch

This figure shows the co-authorship network connecting the top 25 collaborators of U. Bruntsch. A scholar is included among the top collaborators of U. Bruntsch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with U. Bruntsch. U. Bruntsch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wandt, H., U. Bruntsch, & W. M. Gallmeier. (2009). Nachsorge beim Mammakarzinom. DMW - Deutsche Medizinische Wochenschrift. 114(28/29). 1130–1136.
2.
Bruntsch, U., et al.. (2008). Mikroangiopathische hämolytische Anämie als Komplikation bei Mitomycin-C-Therapie. DMW - Deutsche Medizinische Wochenschrift. 107(4). 142–145.
3.
4.
Kappauf, Herbert, et al.. (2000). Use of and attitudes held towards unconventional medicine by patients in a department of internal medicine / oncology and haematology. Supportive Care in Cancer. 8(4). 314–322. 43 indexed citations
5.
Schüler, Martin, U. Bruntsch, E. Späth‐Schwalbe, et al.. (1998). Lack of efficacy of recombinant human interleukin-6 in patients with advanced renal cell cancer: results of a phase II study. European Journal of Cancer. 34(5). 754–756. 15 indexed citations
6.
Drechsler, S., U. Bruntsch, Markus Bangerter, et al.. (1997). Comparison of three tropisetron-containing antiemetic regimens in the prophylaxis of acute and delayed chemotherapy-induced emesis and nausea. Supportive Care in Cancer. 5(5). 387–395. 13 indexed citations
7.
Aamdal, Steinar, U. Bruntsch, Jaap Verweij, et al.. (1997). Zeniplatin in advanced malignant melanoma and renal cancer: phase II studies with unexpected nephrotoxicity. Cancer Chemotherapy and Pharmacology. 40(5). 439–443. 9 indexed citations
8.
Kaplan, Steven, A.-R. Hanauske, N. Pavlidis, et al.. (1996). Single agent activity of rhizoxin in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group. British Journal of Cancer. 73(3). 403–405. 20 indexed citations
9.
Catimel, G., Jan B. Vermorken, M. Clavel, et al.. (1994). A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. Annals of Oncology. 5(6). 543–547. 108 indexed citations
10.
Verweij, Jaap, J. Wanders, Anette Lynge Nielsen, et al.. (1994). Phase II studies of Elsamitrucin in breast cancer, colorectal cancer, non-small cell lung cancer and ovarian cancer. Annals of Oncology. 5(4). 375–376. 9 indexed citations
11.
Bruntsch, U., S. Drechsler, W. Eiermann, et al.. (1992). Prevention of Chemotherapy-Induced Nausea and Emesis in Patients Responding Poorly to Previous Antiemetic Therapy. Drugs. 43(Supplement 3). 23–26. 12 indexed citations
12.
Danhauser-Riedl, S., U. Bruntsch, M. Peukert, et al.. (1991). Phase I Study of Weekly Oral Miltefosine (Hexadecyl-Phosphocholine) in Cancer Patients. Oncology Research and Treatment. 14(5). 392–400. 14 indexed citations
13.
Gundersen, S., P Dombernowsky, F. Cavalli, et al.. (1989). TCNU (LS 2667), a new active drug in the treatment of advanced colorectal cancer. European Journal of Cancer and Clinical Oncology. 25(7). 1095–1097. 7 indexed citations
14.
Abele, R, M. Clavel, P. Dodion, et al.. (1987). The EORTC early clinical trials cooperative group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas. European Journal of Cancer and Clinical Oncology. 23(12). 1921–1924. 92 indexed citations
15.
Bruntsch, U., P. Dodion, W.W. ten Bokkel Huinink, et al.. (1986). Primary resistance of renal adenocarcinoma to 1,2,4-triglycidylurazol (TGU, NSC 332488), a new triexpoxide cytostatic agent — A phase II study of the EORTC early clinical trials group. European Journal of Cancer and Clinical Oncology. 22(6). 697–699. 2 indexed citations
16.
Alberto, P., Marcel Rozencweig, M. Clavel, et al.. (1986). Phase II study of 5?-deoxy-5-fluorouridine (doxifluridine) in advanced malignant melanoma. Cancer Chemotherapy and Pharmacology. 16(1). 78–9. 13 indexed citations
17.
Bruntsch, U., et al.. (1984). Lack of response in nine patients with breast cancer treated with fibroblast interferon. Cancer Chemotherapy and Pharmacology. 13(1). 39–42. 7 indexed citations
18.
Bruntsch, U., et al.. (1983). [Chemotherapy of epithelial ovarian carcinoma].. PubMed. 125(44). 993–5. 1 indexed citations
19.
Dodion, P., U. Bruntsch, & W. M. Gallmeier. (1982). Combination chemotherapy with cisplatin, methotrexate, bleomycin, and vincristine (CABO) in squamous cell carcinoma of the head and neck. Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles). 1. 199–203. 1 indexed citations
20.
Gallmeier, W. M., et al.. (1973). T and B lymphocytes in Hodgkin's disease. Journal of Cancer Research and Clinical Oncology. 80(3). 247–54. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by P Cappelaere Breakdown of academic impact, for papers by Junichi Kaganoi Breakdown of academic impact, for papers by Carlos García Girón Breakdown of academic impact, for papers by Dolores Gallardo‐Rincón Breakdown of academic impact, for papers by Xavier Fabregat Breakdown of academic impact, for papers by Thomas Cerny Breakdown of academic impact, for papers by K. Buser Breakdown of academic impact, for papers by Siu‐Fun Wong Breakdown of academic impact, for papers by Suzanne M. Fields Breakdown of academic impact, for papers by Ilaria Imarisio
Rankless by CCL
2026